Immatics Stock Trading Higher As Cell Therapy Program Shows Anti-Tumor Activities In Pretreated Cancer Patients

Immatics NV IMTX has announced a clinical data update from the dose-escalation cohorts of the ongoing Phase 1 trial evaluating its ACTengine product candidates IMA201, IMA202, and IMA203.

• Data showed that first anti-tumor activity with 9 out of 10 evaluable patients showing disease control.
• Tumor shrinkage was observed in 8 out of 10 patients, including one partial response.
• Robust T cell engraftment and persistence post-infusion was observed across all three trials and were measurable for up to 9 months.
• T cell infiltration into the tumor site was observed in all evaluable patients with available serial tumor biopsies.
• Overall, all product candidates demonstrated a manageable safety and tolerability profile.
• Most frequent adverse events included expected cytopenias associated with lymphodepletion in all patients and transient low to moderate cytokine release syndrome observed in most patients.
• No dose-limiting toxicities were observed in patients treated with IMA201 and IMA202.
• One patient receiving IMA203 at dose level 2 experienced dose-limiting toxicity that was transient and fully resolved within 48 hours after onset.
• Price Action: IMTX shares are trading 28.9% higher at $14.99 in market trading hours on the last check Wednesday.